Early Flozin Use Tied to Improved LA Strain in ACS With Diab
Empagliflozin was initiated in eligible patients with ACS and type 2 diabetes. Patients not started on empagliflozin served as a control group. LA strain was assessed at baseline and at 3- to 6-month follow-up with transthoracic echo and 2D- echo. 44 participants (n =22 in each group) completed the study, representing 88% follow-up. Baseline characteristics were similar, except HbA1c was higher in the empagliflozin group. A significant increase in LA reservoir, conduit, and the contractile strain was seen in the empagliflozin group at follow-up in the 4-chamber view. The two-chamber view demonstrated a significant increase with empagliflozin in LA reservoir (P =.005) and contractile strain (P =.024), but not LA conduit strain (P =.193). The difference in change between groups from baseline to follow-up was significant for LA reservoir and contractile strain in the two-chamber and four-chamber views. HbA1c decreased significantly from baseline to follow-up in the empagliflozin group, but not in the control group. Changes in LA reservoir and contractile strain from baseline to follow-up were significantly associated with changes in HbA1c (P =.004 and P =.016, respectively).

Source: https://www.medscape.com/viewarticle/976562?src=rss